Skip to main content
      Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage. In this compilation from the past week we talk about - HIV and arthritis - Hyperuricemia in PsA - An odd kind of dermatomyositis - Running out of options in Difficult RA Listen here or on your podcast program in your car.
      Check out our "Virtual ACR2020 Playbook" to plan how you will take in and consume ACR20 from home and in your fuzzy sl

      Dr. John Cush RheumNow

      5 years ago
      Check out our "Virtual ACR2020 Playbook" to plan how you will take in and consume ACR20 from home and in your fuzzy slippers. https://t.co/5bsOFFXEMZ
      #LTF
      Please wear your mask https://t.co/dzN0SDLb0T

      Dr. John Cush RheumNow

      5 years ago
      #LTF Please wear your mask https://t.co/dzN0SDLb0T
      Spanish cross-sectional study of 2,102 Rheumatic patients compared meds to COVID risk and showed Denosumab (0.58), zole

      Dr. John Cush RheumNow

      5 years ago
      Spanish cross-sectional study of 2,102 Rheumatic patients compared meds to COVID risk and showed Denosumab (0.58), zoledronate (0.62), calcium were negatively associated with COVID-19. Why? is it that they are less "sick"? https://t.co/BNbwsCz0rA
      Eosinophilia in #RA is either due to a secondary problem (endemic parasitosis, drug hypersensitivity, etc) or may be ass

      Dr. John Cush RheumNow

      5 years ago
      Eosinophilia in #RA is either due to a secondary problem (endemic parasitosis, drug hypersensitivity, etc) or may be associated with more severe RA - it is not associated with extraarticular manifestations of RA. https://t.co/J9rOA3cWC4
      Pearls from the Virtual ACR20 Playbook: Dr. Meral El Ramahi

      Dr. El Ramahi reviews pearls in the RheumNow virtual ACR playbook. 

      If you need a plan for this weekend's ACR meeting, check out and download our latest, "Virtual ACR 2020 Playbook". The playbook covers: setting virtual learning goals, sessions you probably shouldn't miss, how to still have peer interactions, what to do if you only have time to "dabble' - and more.
      Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Ps

      Dr. John Cush RheumNow

      5 years ago
      Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG
      The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 
      Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory suppo

      Dr. John Cush RheumNow

      5 years ago
      Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital (OR=2.7, 1.7, 2.7) https://t.co/OGmarAfzLM
      ×